Ignite Creation Date:
2025-12-25 @ 3:37 AM
Ignite Modification Date:
2026-04-23 @ 9:39 PM
Study NCT ID:
NCT02997202
Status:
COMPLETED
Last Update Posted:
2025-01-17
First Post:
2016-12-01
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Sponsor:
Astellas Pharma Global Development, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-08-16
Start Date Type:
ACTUAL
Primary Completion Date:
2023-01-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-05-09
Completion Date Type:
ACTUAL
First Submit Date:
2016-12-01
First Submit QC Date:
None
Study First Post Date:
2016-12-19
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2024-05-06
Results First Submit QC Date:
None
Results First Post Date:
2024-09-19
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2024-09-19
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2025-01-15
Last Update Post Date:
2025-01-17
Last Update Post Date Type:
ACTUAL